Glioblastoma (GBM) is one of the most aggressive tumors in humans. Despite multimodal therapeutic interventions, the median survival of GBM patients is still restricted to about 15 months. One of the main reasons for the observed treatment resistance and concomitant tumor recurrence is the invasive growth of GBM preventing a total tumor resection as well as profound changes in the tumor microenvironment. The immune system plays a significant role in the development of GBM, particularly tumor-associated macrophages (TAMs). Learn more about macrophages in Glioblastoma.
